Circulation

FEBRUARY 5, 2024

This scientific statement discusses the mechanism of arrhythmias, pharmacological treatment options, and distinct aspects of pharmacokinetics for the fetus and neonate.

Pharmacology 78

Pharmacology Arrhythmia Physiology Circulation 78

Nature Reviews - Cardiology

MARCH 25, 2024

Nature Reviews Cardiology, Published online: 26 March 2024; doi:10.1038/s41569-024-00997-0 In this Review, Bozkurt provides an overview of the management of patients with heart failure across the full range of left ventricular ejection fraction, derived from the recommendations in the latest US and European guidelines.

Heart Failure 98

Heart Failure Pharmacology 98

Journal of Clinical Investigation - Cardiology

NOVEMBER 15, 2024

The sensory cells that transduce the signals for hearing and balance are highly specialized mechanoreceptors called hair cells that together with supporting cells comprise the sensory epithelia of the inner ear.

Pharmacology 52

Pharmacology Physiology 52

Journal of Cardiovascular Pharmacology

JUNE 3, 2024

A variety of technologies, including network pharmacology, RNA-sequencing, immunohistochemistry, and Western blotting were performed to investigate its underlying mechanisms.

Pharmacology 40

Pharmacology Hypertension Technology Article 40

Open Heart

NOVEMBER 17, 2022

Associations between pharmacological treatment and long-term survival were analysed using Cox proportional hazards models. Methods From Swedish medical registers, all patients diagnosed with AD in 2006–2015 were identified. Results Of 3951 patients hospitalised with acute AD, 3046 (77%) were discharged and alive at 30 days.

Pharmacology 52

Pharmacology Aortic Outcomes 52

Stroke Journal

FEBRUARY 1, 2024

In this study, we investigated the effect of pharmacological activation of MerTK-mediated efferocytosis using the Gas6 in intracranial aneurysms.Methods:We used 10-week-old male C57BL/6J mice. Our previous study suggested that MerTK knockout mice increased the rupture rate of intracranial aneurysms due to impaired efferocytosis.

Aneurysm 40

Aneurysm Pharmacology Hypertension Strokes 40

Hypertension Journal

JANUARY 2, 2024

Pharmacological inhibition of EGFR or downstream ER stress may be a promising therapeutic strategy for preventing aneurysm rupture and subarachnoid hemorrhage.

Aneurysm 45

Aneurysm Pharmacology Atherosclerosis Hemorrhage 45

Cardiovascular Diabetology

JUNE 30, 2024

The available evidence on the impact of specific non-pharmacological interventions on glycaemic control is currently limited. Consequently, there is a need to determine which interventions could provide the mo.

Pharmacology 144

Pharmacology Diabetes 144

Becker's Hospital Review - Cardiology

AUGUST 27, 2024

22 in Diabetes, Obesity and Metabolism: A Journal of Pharmacology and Therapeutics. GLP-1s reduced mortality and complications from cardiovascular events, according to a study published Aug.

Pharmacology 113

Pharmacology Obesity Diabetes 113

JAMA Cardiology

OCTOBER 26, 2024

This substudy of the Danish-German (DanGer) Shock randomized clinical trial investigates if the use of a microaxial flow pump reduces the need for pharmacological support and what the effects are on hemodynamics and lactate clearance in patients with ST-elevation myocardial infarction–induced cardiogenic shock.

Cardiogenic Shock 102

Cardiogenic Shock Myocardial Infarction Pharmacology 102

Journal of Clinical Investigation - Cardiology

SEPTEMBER 3, 2024

Tumor reliance on glycolysis is a hallmark of cancer. Immunotherapy is more effective in controlling glycolysis-low tumors lacking lactate dehydrogenase (LDH) due to reduced tumor lactate efflux and enhanced glucose availability within the tumor microenvironment (TME).

Pharmacology 52

Pharmacology Cancer 52

HeartRhythm

APRIL 30, 2024

Microneurography showed that central alpha-2 agonists such as clonidine could acutely suppress sympathetic nerve activity (SNA). The acute and long-term neuromodulation effects of clonidine are unknown.

Pharmacology 40

Pharmacology 40

Frontiers in Cardiovascular Medicine

NOVEMBER 14, 2024

However, in two patients, LDL-C levels increased by 5.42% and 9.03% after pharmacological treatment. mmol/L (reduced by 15.40%) (P < 0.001), and LDL-C levels decreased on average by 2.73 mmol/L mmol/L (reduced by 13.46%) (P = 0.014). mmol/L (reduced by 15.40%) (P < 0.001), and LDL-C levels decreased on average by 2.73 mmol/L

Transplant 52

Transplant Pharmacology Cholesterol Hospital 52

The New England Journal of Medicine

MAY 12, 2024

In April 1964, leading cardiologists, cardiovascular surgeons, and pathologists convened in London for a 2-day symposium to discuss a relatively new disease entity that we now know as obstructive hypertrophic cardiomyopathy (HCM).1 1 The proceedings kicked off with a comment by the group’s chairman: “I have never before taken.

Cardiomyopathy 40

Cardiomyopathy Pharmacology 40

Journal of Cardiovascular Pharmacology

DECEMBER 12, 2023

An abstract is unavailable. This article is available as a PDF only.

Pharmacology 52

Pharmacology Article 52

Journal of Clinical Investigation - Cardiology

OCTOBER 15, 2024

Although no pharmacological interventions are yet approved for CUD, we present the most promising pharmacological interventions being tested.

Pharmacology 126

Pharmacology Innovation Risk Factors 126

Journal of Cardiovascular Pharmacology

SEPTEMBER 12, 2024

Human induced pluripotent stem cells (hiPSC) and atrial hiPSC-derived cardiomyocytes (hiPSC-CM) have entered the arena of preclinical AF research. A central question is whether they reproduce the physiological contribution of atrial selective potassium currents (such as the ultrarapid potassium current, IKur) to repolarization.

Pharmacology 40

Pharmacology CMS Electrophysiology Physiology 40

Stroke Journal

FEBRUARY 1, 2024

These results support the hypothesis that PFKFB3 inhibitors may be used as a novel pharmacological treatment for reducing delayed cell death after ischemic stroke. Future studies are underway to investigate the molecular mechanisms and cell types involved in the protection conferred by PFKFB3 blockade in the context of ischemic stroke.

Pharmacology 40

Pharmacology Strokes Stroke 40

HCPLive

SEPTEMBER 26, 2024

The FDA approves Cobenfy, the first pharmacological approach to treating schizophrenia since the 1970s.

Pharmacology 83

Pharmacology 83

HeartRhythm

APRIL 30, 2024

Loss-of-function SCN5A channelopathies, such as Brugada syndrome (BrS), are cardiac disorders marked by diminished sodium current (INa), conduction slowing, and lethal arrhythmias.

Pharmacology 40

Pharmacology Defibrillator Innovation Arrhythmia 40

Med Page Today

DECEMBER 12, 2023

Preventive Services Task Force (USPSTF) plans to recommend intensive behavioral interventions -- but not pharmacologic therapies -- for kids with a high body mass index (BMI). (MedPage Today) -- The U.S. In its draft recommendation statement.

Obesity 124

Obesity BMI Pharmacology 124

HCPLive

JUNE 26, 2024

Jennifer Goldman, RPh, PharmD, discusses how the pharmacologic advancements in recent years have shifted discussion around lipid, and cardiovascular risk, management in diabetes.

Diabetes 81

Diabetes Pharmacology 81

Journal of Clinical Investigation - Cardiology

NOVEMBER 15, 2024

Leveraging these findings, pharmacologic targeting of lactate production augments efficacy of anti-CD47 therapy. Mechanistically, lactylated histone interacts with the heterochromatin component chromobox protein homolog 3 (CBX3).

Pharmacology 104

Pharmacology Cancer 104

Heart BMJ

JUNE 25, 2024

Despite the existence of well-established risk factors and effective pharmacological treatments for major cardiovascular disease (CVD), these conditions remain among the leading causes of premature death and disability, exerting a substantial burden on health systems worldwide.

Pharmacology 59

Pharmacology Blood Pressure Risk Factors Cardiovascular Disease 59

HCPLive

SEPTEMBER 30, 2024

Phentolamine ophthalmic solution 0.75% effectively reversed pharmacologically-induced pupil dilation in the MIRA-2 and MIRA-3 clinical trials.

Pharmacology 52

Pharmacology 52

HeartRhythm

APRIL 30, 2024

Atrial fibrillation (AF) in children is rare. Chemical cardioversion using oral flecainide and ß-blockade is a well-described practice in adults. No data as to the safety and efficacy of this practice in pediatric patients is available.

Atrial Fibrillation 40

Atrial Fibrillation Pediatrics Pharmacology 40

HeartRhythm

APRIL 30, 2024

Contemporary antiarrhythmic treatment of Timothy syndrome 1 (TS1) is inadequate to prevent sudden cardiac death. We thus developed a knock-in TS1 porcine model that reproduces all cardinal features of the human disease and as such represents a unique platform for drug testing.

Sudden Cardiac Death 40

Sudden Cardiac Death Pharmacology Electrophysiology Arrhythmia 40

HCPLive

JULY 20, 2024

At 24 weeks, the oral therapy was well-tolerated and the safety profile remained in line with previous brepocitinib studies and the pharmacological class.

Pharmacology 59

Pharmacology 59

Circulation

NOVEMBER 11, 2024

However, there are currently no pharmacological treatments for CAVD, and the discovery of de novo molecules targeting a specific protein is a time-intensive and financially demanding process. This provides an efficient and automated method for developing novel molecules with specific molecular and pharmacological properties.

Pharmacology 40

Pharmacology Aortic valve Aortic Circulation 40

Journal of Clinical Investigation - Cardiology

SEPTEMBER 3, 2024

Together, these findings offer critical insights into the functional role of LSGLP-1R neurons in the physiological regulation of energy homeostasis and delineate their instrumental role in mediating the pharmacological efficacy of liraglutide.

Pharmacology 123

Pharmacology Physiology Obesity 123

Stroke Journal

FEBRUARY 1, 2024

Stroke, Volume 55, Issue Suppl_1 , Page ATP312-ATP312, February 1, 2024. Traumatic brain injury (TBI) afflicts 70 million people worldwide annually and is the 3rd overall risk factor for developing Alzheimer's disease (AD), behind genetics and aging.

Pharmacology 40

Pharmacology Risk Factors Strokes Stroke 40

HCPLive

JULY 8, 2024

Emerging treatments for CSA include hypochlorite phrenic nerve stimulation and pharmacological intervention, Badr told HCPLive.

Pharmacology 59

Pharmacology 59

HCPLive

OCTOBER 10, 2024

Findings highlight high healthcare resource utilization and costs but low psychotherapy utilization, frequent relapse, and pharmacologic therapy discontinuation.

Pharmacology 52

Pharmacology 52

Nature Reviews - Cardiology

JANUARY 25, 2024

Nature Reviews Cardiology, Published online: 26 January 2024; doi:10.1038/s41569-023-00986-9 In this Review, Varga and colleagues provide an overview of the evidence on immune checkpoint inhibitor-induced heart failure and cardiac dysfunction that is unrelated to myocarditis, and discuss how pharmacological targeting of immune checkpoints might be (..)

Heart Failure 91

Heart Failure Physiology Pharmacology 91

Frontiers in Cardiovascular Medicine

MARCH 12, 2024

In this narrative review, we discuss the pathophysiology of CS, novel phenotypes, evolving definitions and staging systems, currently available pharmacologic and device-based therapies, standardized, team-based management protocols, and regionalized systems-of-care aimed at improving shock outcomes.

Cardiogenic Shock 145

Cardiogenic Shock Pharmacology Outcomes Research 145

Journal of Clinical Investigation - Cardiology

SEPTEMBER 3, 2024

Emerging approaches, including cellular and gene therapy and novel pharmacologic approaches, are described. Current and emerging approaches to treat cancer therapy–induced dry mouth are presented using radiation-induced salivary dysfunction as a model. Limitations of current sialagogues and salivary analogues are presented.

Cancer 124

Cancer Quality of Life Anatomy Pharmacology 124

Frontiers in Cardiovascular Medicine

FEBRUARY 20, 2024

Results Pharmacological/non-pharmacological secondary prevention methods have been efficiently applied. Baseline aggregometry indicated platelet hyperactivity, decreasing gradually and being significantly reduced late, at 12 months ( p  < 0.05).

Laboratory 111

Laboratory Pharmacology Biomarkers 111